{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:59:38Z","timestamp":1790492378370,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Due to the limited utility of Bacillus Calmette\u2013Gu\u00e9rin (BCG), the only approved vaccine available for tuberculosis, there is a need to develop a more effective and safe vaccine. We evaluated the safety and efficacy of a dry powder aerosol (DPA) formulation of BCG encapsulated alginate particle (BEAP) and the conventional intradermal BCG immunization in infant rhesus macaques (<jats:italic>Macaca mulatta)<\/jats:italic>. The infant macaques were immunized intratracheally with DPA of BEAP into the lungs. Animals were monitored for their growth, behaviour, any adverse and allergic response. The protective efficacy of BEAP was estimated by the <jats:italic>ex-vivo<\/jats:italic> H37Rv infection method. Post-immunization with BEAP, granulocytes count, weight gain, chest radiography, levels of liver secreted enzymes, cytokines associated with inflammation like TNF and IL-6 established that BEAP is non-toxic and it does not elicit an allergic response. The T cells isolated from BEAP immunized animals\u2019 blood, upon stimulation with <jats:italic>M.tb<\/jats:italic> antigen, secreted high levels of IFN-\u03b3, TNF, IL-6 and IL-2. The activated T cells from BEAP group, when co-cultured with <jats:italic>M.tb<\/jats:italic> infected macrophages, eliminated largest number of infected macrophages compared to the BCG and control group. This study suggests the safety and efficacy of BEAP in Non-human primate model.<\/jats:p>","DOI":"10.1038\/s41598-021-82614-5","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T11:08:10Z","timestamp":1612436890000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The safety and efficacy of BCG encapsulated alginate particle (BEAP) against M.tb H37Rv infection in Macaca mulatta : A pilot study"],"prefix":"10.1038","volume":"11","author":[{"given":"Ashwani","family":"Kesarwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kshama","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakriti","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Varsha","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puja S.","family":"Nagpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surender","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perumal","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"82614_CR1","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/j.ijid.2019.02.036","volume":"80S","author":"D de Gijsel","year":"2019","unstructured":"de Gijsel, D. & von Reyn, C. F. A breath of fresh Air: BCG prevents adult pulmonary tuberculosis. Int. J. Infect. Dis. 80S, S6\u2013S8. https:\/\/doi.org\/10.1016\/j.ijid.2019.02.036 (2019).","journal-title":"Int. J. Infect. Dis."},{"key":"82614_CR2","doi-asserted-by":"publisher","first-page":"e1655","DOI":"10.1016\/S2214-109X(19)30444-9","volume":"7","author":"P Roy","year":"2019","unstructured":"Roy, P. et al. Potential effect of age of BCG vaccination on global paediatric tuberculosis mortality: a modelling study. Lancet Glob. Health 7, e1655\u2013e1663. https:\/\/doi.org\/10.1016\/S2214-109X(19)30444-9 (2019).","journal-title":"Lancet Glob. Health"},{"key":"82614_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s13312-014-0440-x","volume":"51","author":"TJ John","year":"2014","unstructured":"John, T. J. Tuberculosis control in India: Why are we failing?. Indian Pediatr. 51, 523\u2013527. https:\/\/doi.org\/10.1007\/s13312-014-0440-x (2014).","journal-title":"Indian Pediatr."},{"key":"82614_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fimmu.2020.00316","volume":"11","author":"SHE Kaufmann","year":"2020","unstructured":"Kaufmann, S. H. E. Vaccination against tuberculosis: revamping BCG by molecular genetics guided by immunology. Front Immunol. 11, 316. https:\/\/doi.org\/10.3389\/fimmu.2020.00316 (2020).","journal-title":"Front Immunol."},{"key":"82614_CR5","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1128\/iai.71.4.1672-1679.2003","volume":"71","author":"MA Horwitz","year":"2003","unstructured":"Horwitz, M. A. & Harth, G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun. 71, 1672\u20131679. https:\/\/doi.org\/10.1128\/iai.71.4.1672-1679.2003 (2003).","journal-title":"Infect Immun."},{"key":"82614_CR6","doi-asserted-by":"publisher","first-page":"e3869","DOI":"10.1371\/journal.pone.0003869","volume":"3","author":"R Jain","year":"2008","unstructured":"Jain, R. et al. Enhanced and enduring protection against tuberculosis by recombinant BCG-Ag85C and its association with modulation of cytokine profile in lung. PLoS ONE 3, e3869. https:\/\/doi.org\/10.1371\/journal.pone.0003869 (2008).","journal-title":"PLoS ONE"},{"key":"82614_CR7","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.tube.2007.06.002","volume":"87","author":"I Sugawara","year":"2007","unstructured":"Sugawara, I., Li, Z., Sun, L., Udagawa, T. & Taniyama, T. Recombinant BCG Tokyo (Ag85A) protects cynomolgus monkeys (Macaca fascicularis) infected with H37Rv Mycobacterium tuberculosis. Tuberculosis (Edinb) 87, 518\u2013525. https:\/\/doi.org\/10.1016\/j.tube.2007.06.002 (2007).","journal-title":"Tuberculosis (Edinb)"},{"key":"82614_CR8","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.1016\/j.vaccine.2009.05.048","volume":"27","author":"R Sun","year":"2009","unstructured":"Sun, R. et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 27, 4412\u20134423. https:\/\/doi.org\/10.1016\/j.vaccine.2009.05.048 (2009).","journal-title":"Vaccine"},{"key":"82614_CR9","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/infdis\/jiv503","volume":"213","author":"N Aguilo","year":"2016","unstructured":"Aguilo, N. et al. Pulmonary but not subcutaneous delivery of BCG vaccine confers protection to tuberculosis-susceptible mice by an interleukin 17-dependent mechanism. J Infect. Dis. 213, 831\u2013839. https:\/\/doi.org\/10.1093\/infdis\/jiv503 (2016).","journal-title":"J Infect. Dis."},{"key":"82614_CR10","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.4049\/jimmunol.1400676","volume":"193","author":"PA Darrah","year":"2014","unstructured":"Darrah, P. A. et al. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge. J. Immunol. 193, 1799\u20131811. https:\/\/doi.org\/10.4049\/jimmunol.1400676 (2014).","journal-title":"J. Immunol."},{"key":"82614_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/trstmh\/tru206","volume":"109","author":"ZR Manjaly Thomas","year":"2015","unstructured":"Manjaly Thomas, Z. R. & McShane, H. Aerosol immunisation for TB: matching route of vaccination to route of infection. Trans. R. Soc. Trop. Med. Hyg. 109, 175\u2013181. https:\/\/doi.org\/10.1093\/trstmh\/tru206 (2015).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"82614_CR12","doi-asserted-by":"publisher","unstructured":"Nagpal, P. S., Kesarwani, A., Sahu, P. & Upadhyay, P. Aerosol immunization by alginate coated mycobacterium (BCG\/MIP) particles provide enhanced immune response and protective efficacy than aerosol of plain mycobacterium against M.tb. H37Rv infection in mice. BMC Infect. Dis. 19, 568, https:\/\/doi.org\/10.1186\/s12879-019-4157-2 (2019).","DOI":"10.1186\/s12879-019-4157-2"},{"key":"82614_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1600-0684.2012.00536.x","volume":"41","author":"D Kaushal","year":"2012","unstructured":"Kaushal, D., Mehra, S., Didier, P. J. & Lackner, A. A. The non-human primate model of tuberculosis. J. Med. Primatol. 41, 191\u2013201. https:\/\/doi.org\/10.1111\/j.1600-0684.2012.00536.x (2012).","journal-title":"J. Med. Primatol."},{"key":"82614_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/15287399409531863","volume":"42","author":"S Fernie","year":"1994","unstructured":"Fernie, S., Wrenshall, E., Malcolm, S., Bryce, F. & Arnold, D. L. Normative hematologic and serum biochemical values for adult and infant rhesus monkeys (Macaca mulatta) in a controlled laboratory environment. J. Toxicol. Environ. Health 42, 53\u201372. https:\/\/doi.org\/10.1080\/15287399409531863 (1994).","journal-title":"J. Toxicol. Environ. Health"},{"key":"82614_CR15","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.vaccine.2009.11.004","volume":"28","author":"MK Lalor","year":"2010","unstructured":"Lalor, M. K. et al. Complex cytokine profiles induced by BCG vaccination in UK infants. Vaccine 28, 1635\u20131641. https:\/\/doi.org\/10.1016\/j.vaccine.2009.11.004 (2010).","journal-title":"Vaccine"},{"key":"82614_CR16","first-page":"2029","volume":"16","author":"Q Li","year":"2012","unstructured":"Li, Q. et al. IL-17 and IFN-gamma production in peripheral blood following BCG vaccination and Mycobacterium tuberculosis infection in human. Eur. Rev. Med. Pharmacol. Sci. 16, 2029\u20132036 (2012).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"82614_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/infdis\/jir240","volume":"204","author":"P Aaby","year":"2011","unstructured":"Aaby, P. et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period?. J. Infect. Dis. 204, 245\u2013252. https:\/\/doi.org\/10.1093\/infdis\/jir240 (2011).","journal-title":"J. Infect. Dis."},{"key":"82614_CR18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/INF.0b013e3182458289","volume":"31","author":"S Biering-Sorensen","year":"2012","unstructured":"Biering-Sorensen, S. et al. Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guerin vaccination at first health center contact. Pediatr. Infect. Dis. J 31, 306\u2013308. https:\/\/doi.org\/10.1097\/INF.0b013e3182458289 (2012).","journal-title":"Pediatr. Infect. Dis. J"},{"key":"82614_CR19","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.3389\/fimmu.2019.02806","volume":"10","author":"C Covian","year":"2019","unstructured":"Covian, C. et al. BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design. Front Immunol. 10, 2806. https:\/\/doi.org\/10.3389\/fimmu.2019.02806 (2019).","journal-title":"Front Immunol."},{"issue":"Suppl 3","key":"82614_CR20","doi-asserted-by":"publisher","first-page":"S257","DOI":"10.1086\/313887","volume":"30","author":"S Worku","year":"2000","unstructured":"Worku, S. & Hoft, D. F. In vitro measurement of protective mycobacterial immunity: antigen-specific expansion of T cells capable of inhibiting intracellular growth of bacille Calmette-Guerin. Clin Infect Dis 30(Suppl 3), S257-261. https:\/\/doi.org\/10.1086\/313887 (2000).","journal-title":"Clin Infect Dis"},{"key":"82614_CR21","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1128\/iai.71.4.1763-1773.2003","volume":"71","author":"S Worku","year":"2003","unstructured":"Worku, S. & Hoft, D. F. Differential effects of control and antigen-specific T cells on intracellular mycobacterial growth. Infect. Immun. 71, 1763\u20131773. https:\/\/doi.org\/10.1128\/iai.71.4.1763-1773.2003 (2003).","journal-title":"Infect. Immun."},{"key":"82614_CR22","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/S0140-6736(02)08353-8","volume":"359","author":"GF Black","year":"2002","unstructured":"Black, G. F. et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 359, 1393\u20131401. https:\/\/doi.org\/10.1016\/S0140-6736(02)08353-8 (2002).","journal-title":"Lancet"},{"key":"82614_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1365-2249.2012.04614.x","volume":"169","author":"F Abebe","year":"2012","unstructured":"Abebe, F. Is interferon-gamma the right marker for bacille Calmette-Guerin-induced immune protection? The missing link in our understanding of tuberculosis immunology. Clin. Exp. Immunol. 169, 213\u2013219. https:\/\/doi.org\/10.1111\/j.1365-2249.2012.04614.x (2012).","journal-title":"Clin. Exp. Immunol."},{"key":"82614_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1600-065X.2008.00697.x","volume":"226","author":"KK Hoyer","year":"2008","unstructured":"Hoyer, K. K., Dooms, H., Barron, L. & Abbas, A. K. Interleukin-2 in the development and control of inflammatory disease. Immunol. Rev. 226, 19\u201328. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00697.x (2008).","journal-title":"Immunol. Rev."},{"key":"82614_CR25","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1128\/IAI.65.11.4843-4849.1997","volume":"65","author":"CH Ladel","year":"1997","unstructured":"Ladel, C. H. et al. Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect. Immun. 65, 4843\u20134849. https:\/\/doi.org\/10.1128\/IAI.65.11.4843-4849.1997 (1997).","journal-title":"Infect. Immun."},{"key":"82614_CR26","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/infdis\/jit037","volume":"207","author":"AN Martinez","year":"2013","unstructured":"Martinez, A. N., Mehra, S. & Kaushal, D. Role of interleukin 6 in innate immunity to Mycobacterium tuberculosis infection. J. Infect. Dis. 207, 1253\u20131261. https:\/\/doi.org\/10.1093\/infdis\/jit037 (2013).","journal-title":"J. Infect. Dis."},{"key":"82614_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/jmp.12433","volume":"48","author":"F Min","year":"2019","unstructured":"Min, F., Wang, J., Huang, S., Pan, J. & Zhang, L. In vitro responses of multiple cytokines to purified protein derivative in healthy and naturally Mycobacterium tuberculosis-infected rhesus monkeys (Macaca mulatta). J. Med. Primatol. 48, 329\u2013337. https:\/\/doi.org\/10.1111\/jmp.12433 (2019).","journal-title":"J. Med. Primatol."},{"key":"82614_CR28","doi-asserted-by":"publisher","unstructured":"28Brennan, M. J. et al. The Cross-Species Mycobacterial Growth Inhibition Assay (MGIA) Project, 2010\u20132014. Clin. Vaccine Immunol. https:\/\/doi.org\/10.1128\/CVI.00142-17 (2017).","DOI":"10.1128\/CVI.00142-17"},{"key":"82614_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.vaccine.2009.10.047","volume":"28","author":"K Kolibab","year":"2009","unstructured":"Kolibab, K. et al. A practical in vitro growth inhibition assay for the evaluation of TB vaccines. Vaccine 28, 317\u2013322. https:\/\/doi.org\/10.1016\/j.vaccine.2009.10.047 (2009).","journal-title":"Vaccine"},{"key":"82614_CR30","doi-asserted-by":"publisher","unstructured":"30Marsay, L. et al. Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M. tb). Tuberculosis (Edinb) 93, 551\u2013557, https:\/\/doi.org\/10.1016\/j.tube.2013.04.007 (2013).","DOI":"10.1016\/j.tube.2013.04.007"},{"key":"82614_CR31","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1128\/CVI.00067-09","volume":"16","author":"M Parra","year":"2009","unstructured":"Parra, M. et al. Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis. Clin. Vaccine. Immunol. 16, 1025\u20131032. https:\/\/doi.org\/10.1128\/CVI.00067-09 (2009).","journal-title":"Clin. Vaccine. Immunol."},{"key":"82614_CR32","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1186\/s12879-016-1751-4","volume":"16","author":"A Zelmer","year":"2016","unstructured":"Zelmer, A. et al. A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis. BMC Infect. Dis. 16, 412. https:\/\/doi.org\/10.1186\/s12879-016-1751-4 (2016).","journal-title":"BMC Infect. Dis."},{"key":"82614_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1128\/BR.25.3.331-346.1961","volume":"25","author":"G Middlebrook","year":"1961","unstructured":"Middlebrook, G. Immunological aspects of airborne infection: reactions to inhaled antigens. Bacteriol. Rev. 25, 331\u2013346 (1961).","journal-title":"Bacteriol. Rev."},{"key":"82614_CR34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/02770906809100348","volume":"5","author":"SR Rosenthal","year":"1968","unstructured":"Rosenthal, S. R., McEnery, J. T. & Raisys, N. Aerogenic BCG vaccination against tuberculosis in animal and human subjects. J. Asthma Res. 5, 309\u2013323. https:\/\/doi.org\/10.3109\/02770906809100348 (1968).","journal-title":"J. Asthma Res."},{"key":"82614_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1164\/arrd.1973.107.3.351","volume":"107","author":"WR Barclay","year":"1973","unstructured":"Barclay, W. R. et al. Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guerin. Am. Rev. Respir. Dis. 107, 351\u2013358. https:\/\/doi.org\/10.1164\/arrd.1973.107.3.351 (1973).","journal-title":"Am. Rev. Respir. Dis."},{"key":"82614_CR36","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1128\/CVI.00289-15","volume":"22","author":"AD White","year":"2015","unstructured":"White, A. D. et al. Evaluation of the immunogenicity of mycobacterium bovis BCG delivered by aerosol to the lungs of macaques. Clin. Vaccine. Immunol. 22, 992\u20131003. https:\/\/doi.org\/10.1128\/CVI.00289-15 (2015).","journal-title":"Clin. Vaccine. Immunol."},{"key":"82614_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3389\/fped.2017.00255","volume":"5","author":"ML Decker","year":"2017","unstructured":"Decker, M. L., Grobusch, M. P. & Ritz, N. Influence of age and other factors on cytokine expression profiles in healthy children-a systematic review. Front Pediatr. 5, 255. https:\/\/doi.org\/10.3389\/fped.2017.00255 (2017).","journal-title":"Front Pediatr."},{"key":"82614_CR38","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1128\/IAI.69.2.681-686.2001","volume":"69","author":"H McShane","year":"2001","unstructured":"McShane, H., Brookes, R., Gilbert, S. C. & Hill, A. V. Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect. Immun. 69, 681\u2013686. https:\/\/doi.org\/10.1128\/IAI.69.2.681-686.2001 (2001).","journal-title":"Infect. Immun."},{"key":"82614_CR39","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1128\/CVI.00690-12","volume":"20","author":"AD White","year":"2013","unstructured":"White, A. D. et al. Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques. Clin. Vaccine Immunol. 20, 663\u2013672. https:\/\/doi.org\/10.1128\/CVI.00690-12 (2013).","journal-title":"Clin. Vaccine Immunol."},{"key":"82614_CR40","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","volume":"381","author":"MD Tameris","year":"2013","unstructured":"Tameris, M. D. et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381, 1021\u20131028. https:\/\/doi.org\/10.1016\/S0140-6736(13)60177-4 (2013).","journal-title":"Lancet"},{"key":"82614_CR41","doi-asserted-by":"publisher","first-page":"e1002790","DOI":"10.1371\/journal.pmed.1002790","volume":"16","author":"ZR Manjaly Thomas","year":"2019","unstructured":"Manjaly Thomas, Z. R. et al. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial. PLoS Med. 16, e1002790. https:\/\/doi.org\/10.1371\/journal.pmed.1002790 (2019).","journal-title":"PLoS Med."},{"key":"82614_CR42","doi-asserted-by":"publisher","unstructured":"42Holmgren, I. (1936). Employment of BCG, especially in intravenous injection. Acta Medica Scandinavica,\u00a090(S78), 350\u2013361. https:\/\/doi.org\/10.1111\/j.0954-6820.1936.tb15958.x (1936).","DOI":"10.1111\/j.0954-6820.1936.tb15958.x"},{"key":"82614_CR43","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1128\/IAI.2.5.574-582.1970","volume":"2","author":"WR Barclay","year":"1970","unstructured":"Barclay, W. R., Anacker, R. L., Brehmer, W., Leif, W. & Ribi, E. Aerosol-induced tuberculosis in subhuman primates and the course of the disease after intravenous BCG vaccination. Infect. Immun. 2, 574\u2013582. https:\/\/doi.org\/10.1128\/IAI.2.5.574-582.1970 (1970).","journal-title":"Infect. Immun."},{"key":"82614_CR44","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.tube.2016.09.004","volume":"101","author":"S Sharpe","year":"2016","unstructured":"Sharpe, S. et al. Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: Protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations. Tuberculosis (Edinb) 101, 174\u2013190. https:\/\/doi.org\/10.1016\/j.tube.2016.09.004 (2016).","journal-title":"Tuberculosis (Edinb)"},{"key":"82614_CR45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41586-019-1817-8","volume":"577","author":"PA Darrah","year":"2020","unstructured":"Darrah, P. A. et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature 577, 95\u2013102. https:\/\/doi.org\/10.1038\/s41586-019-1817-8 (2020).","journal-title":"Nature"},{"key":"82614_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40169-017-0151-8","volume":"6","author":"P Kumar","year":"2017","unstructured":"Kumar, P. IFNgamma-producing CD4(+) T lymphocytes: the double-edged swords in tuberculosis. Clin. Transl. Med. 6, 21. https:\/\/doi.org\/10.1186\/s40169-017-0151-8 (2017).","journal-title":"Clin. Transl. Med."},{"key":"82614_CR47","unstructured":"47Okada, M. Novel vaccines against M. tuberculosis. Kekkaku 81, 745\u2013751 (2006)."},{"key":"82614_CR48","doi-asserted-by":"publisher","unstructured":"48McShane, H. Tuberculosis vaccines: beyond bacille Calmette-Guerin. Philos. Trans. R. Soc. Lond. B Biol. Sci. 366, 2782\u20132789, https:\/\/doi.org\/10.1098\/rstb.2011.0097 (2011).","DOI":"10.1098\/rstb.2011.0097"},{"key":"82614_CR49","doi-asserted-by":"publisher","first-page":"8533","DOI":"10.1038\/ncomms9533","volume":"6","author":"D Kaushal","year":"2015","unstructured":"Kaushal, D. et al. Mucosal vaccination with attenuated Mycobacterium tuberculosis induces strong central memory responses and protects against tuberculosis. Nat. Commun. 6, 8533. https:\/\/doi.org\/10.1038\/ncomms9533 (2015).","journal-title":"Nat. Commun."},{"key":"82614_CR50","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/infdis\/jiz117","volume":"221","author":"D Kaushal","year":"2020","unstructured":"Kaushal, D. The comeback kid: BCG. J. Infect. Dis. 221, 1031\u20131032. https:\/\/doi.org\/10.1093\/infdis\/jiz117 (2020).","journal-title":"J. Infect. Dis."},{"key":"82614_CR51","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fimmu.2017.00407","volume":"8","author":"JI Moliva","year":"2017","unstructured":"Moliva, J. I., Turner, J. & Torrelles, J. B. Immune responses to bacillus calmette-guerin vaccination: Why do they fail to protect against mycobacterium tuberculosis?. Front. Immunol. 8, 407. https:\/\/doi.org\/10.3389\/fimmu.2017.00407 (2017).","journal-title":"Front. Immunol."},{"key":"82614_CR52","doi-asserted-by":"publisher","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","volume":"8","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 8, e1000412. https:\/\/doi.org\/10.1371\/journal.pbio.1000412 (2010).","journal-title":"PLoS Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82614-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82614-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82614-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T03:09:55Z","timestamp":1670036995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82614-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["82614"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-82614-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]},"assertion":[{"value":"6 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3049"}}